Sagimet Biosciences (SGMT) KOL Event summary

Introduction and agenda

• Event focused on the development of TVB-3567, a novel FASN inhibitor for moderate to severe acne, following strong phase three results for denifanstat in China, with presentations by company leadership and KOL Dr. Neal Bhatia.

• Agenda included company overview, market opportunity, clinical data review, development plans, and Q&A.

• Forward-looking statements and associated risks were highlighted at the outset.

KOL background and credentials

• Dr. Neal Bhatia, board-certified dermatologist, Director of Clinical Dermatology at Therapeutics Clinical Research, past Vice President of the American Academy of Dermatology, and Chief Medical Editor of Practical Dermatology, served as the key opinion leader and provided expert commentary.

Market insights and analysis

• Global acne market projected to reach $17 billion in the next decade, with the U.S. accounting for about 50% of growth and 5.1 million U.S. patients seeking professional treatment annually.

• 70% of patients presenting to dermatologists have moderate to severe disease, most requiring chronic management.

• Over 50 million people in the US and 640 million globally are affected by acne, highlighting a significant unmet need.

• Oral therapies are preferred due to lower adherence rates with topical treatments, with 30–40% of patients not adhering to topical regimens.

• Limited innovation in acne treatment over the past 40 years underscores the importance of new mechanisms of action.